Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma

Beatriz Sánchez-Espiridión, Ana M. Martin-Moreno, Carlos Montalbán, L. Jeffrey Medeiros, Francisco Vega, Anas Younes, Miguel A. Piris, Juan F. Garcia

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

A subset of patients with advanced classical Hodgkin's lymphoma is refractory to standard therapies. Therefore, it is relevant to identify new biologically-based prognostic markers. Recently, tumor associated macrophages have been proposed as a factor that predicts survival, although contradictory results have also been reported. Here we analyzed four macrophage markers (CD68, CD163, LYZ, and STAT1) using immunohistochemistry and automated quantification, in two independent series of advanced classical Hodgkin's lymphoma (n=266 and 103 patients, respectively). Our results did not confirm that specific macrophage immunohistochemical markers could be used as surrogates for gene expression profiling studies. Survival analyses did not show correlation between CD163, LYZ or STAT1 and either failure-free or disease-specific survival. There was an association between CD68 and disease-specific survival, but it was not consistent in both series. In conclusion, individual tumor associated macrophage markers cannot be used to predict outcome before technical standardization and prospective validation in independent series of patients with comparable stages and treatments.

Original languageEnglish
Pages (from-to)1080-1084
Number of pages5
JournalHaematologica
Volume97
Issue number7
DOIs
StatePublished - Jul 1 2012
Externally publishedYes

Fingerprint

Tumor Biomarkers
Hodgkin Disease
Macrophages
Survival
Gene Expression Profiling
Survival Analysis
Neoplasms
Immunohistochemistry
Therapeutics

Keywords

  • Hodgkin's lymphoma
  • Outcome
  • Tumor associated macrophages

ASJC Scopus subject areas

  • Hematology

Cite this

Sánchez-Espiridión, B., Martin-Moreno, A. M., Montalbán, C., Jeffrey Medeiros, L., Vega, F., Younes, A., ... Garcia, J. F. (2012). Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica, 97(7), 1080-1084. https://doi.org/10.3324/haematol.2011.055459

Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. / Sánchez-Espiridión, Beatriz; Martin-Moreno, Ana M.; Montalbán, Carlos; Jeffrey Medeiros, L.; Vega, Francisco; Younes, Anas; Piris, Miguel A.; Garcia, Juan F.

In: Haematologica, Vol. 97, No. 7, 01.07.2012, p. 1080-1084.

Research output: Contribution to journalArticle

Sánchez-Espiridión, B, Martin-Moreno, AM, Montalbán, C, Jeffrey Medeiros, L, Vega, F, Younes, A, Piris, MA & Garcia, JF 2012, 'Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma', Haematologica, vol. 97, no. 7, pp. 1080-1084. https://doi.org/10.3324/haematol.2011.055459
Sánchez-Espiridión B, Martin-Moreno AM, Montalbán C, Jeffrey Medeiros L, Vega F, Younes A et al. Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. Haematologica. 2012 Jul 1;97(7):1080-1084. https://doi.org/10.3324/haematol.2011.055459
Sánchez-Espiridión, Beatriz ; Martin-Moreno, Ana M. ; Montalbán, Carlos ; Jeffrey Medeiros, L. ; Vega, Francisco ; Younes, Anas ; Piris, Miguel A. ; Garcia, Juan F. / Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma. In: Haematologica. 2012 ; Vol. 97, No. 7. pp. 1080-1084.
@article{cf124adc533143d0976d502070a1f388,
title = "Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma",
abstract = "A subset of patients with advanced classical Hodgkin's lymphoma is refractory to standard therapies. Therefore, it is relevant to identify new biologically-based prognostic markers. Recently, tumor associated macrophages have been proposed as a factor that predicts survival, although contradictory results have also been reported. Here we analyzed four macrophage markers (CD68, CD163, LYZ, and STAT1) using immunohistochemistry and automated quantification, in two independent series of advanced classical Hodgkin's lymphoma (n=266 and 103 patients, respectively). Our results did not confirm that specific macrophage immunohistochemical markers could be used as surrogates for gene expression profiling studies. Survival analyses did not show correlation between CD163, LYZ or STAT1 and either failure-free or disease-specific survival. There was an association between CD68 and disease-specific survival, but it was not consistent in both series. In conclusion, individual tumor associated macrophage markers cannot be used to predict outcome before technical standardization and prospective validation in independent series of patients with comparable stages and treatments.",
keywords = "Hodgkin's lymphoma, Outcome, Tumor associated macrophages",
author = "Beatriz S{\'a}nchez-Espiridi{\'o}n and Martin-Moreno, {Ana M.} and Carlos Montalb{\'a}n and {Jeffrey Medeiros}, L. and Francisco Vega and Anas Younes and Piris, {Miguel A.} and Garcia, {Juan F.}",
year = "2012",
month = "7",
day = "1",
doi = "10.3324/haematol.2011.055459",
language = "English",
volume = "97",
pages = "1080--1084",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "7",

}

TY - JOUR

T1 - Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma

AU - Sánchez-Espiridión, Beatriz

AU - Martin-Moreno, Ana M.

AU - Montalbán, Carlos

AU - Jeffrey Medeiros, L.

AU - Vega, Francisco

AU - Younes, Anas

AU - Piris, Miguel A.

AU - Garcia, Juan F.

PY - 2012/7/1

Y1 - 2012/7/1

N2 - A subset of patients with advanced classical Hodgkin's lymphoma is refractory to standard therapies. Therefore, it is relevant to identify new biologically-based prognostic markers. Recently, tumor associated macrophages have been proposed as a factor that predicts survival, although contradictory results have also been reported. Here we analyzed four macrophage markers (CD68, CD163, LYZ, and STAT1) using immunohistochemistry and automated quantification, in two independent series of advanced classical Hodgkin's lymphoma (n=266 and 103 patients, respectively). Our results did not confirm that specific macrophage immunohistochemical markers could be used as surrogates for gene expression profiling studies. Survival analyses did not show correlation between CD163, LYZ or STAT1 and either failure-free or disease-specific survival. There was an association between CD68 and disease-specific survival, but it was not consistent in both series. In conclusion, individual tumor associated macrophage markers cannot be used to predict outcome before technical standardization and prospective validation in independent series of patients with comparable stages and treatments.

AB - A subset of patients with advanced classical Hodgkin's lymphoma is refractory to standard therapies. Therefore, it is relevant to identify new biologically-based prognostic markers. Recently, tumor associated macrophages have been proposed as a factor that predicts survival, although contradictory results have also been reported. Here we analyzed four macrophage markers (CD68, CD163, LYZ, and STAT1) using immunohistochemistry and automated quantification, in two independent series of advanced classical Hodgkin's lymphoma (n=266 and 103 patients, respectively). Our results did not confirm that specific macrophage immunohistochemical markers could be used as surrogates for gene expression profiling studies. Survival analyses did not show correlation between CD163, LYZ or STAT1 and either failure-free or disease-specific survival. There was an association between CD68 and disease-specific survival, but it was not consistent in both series. In conclusion, individual tumor associated macrophage markers cannot be used to predict outcome before technical standardization and prospective validation in independent series of patients with comparable stages and treatments.

KW - Hodgkin's lymphoma

KW - Outcome

KW - Tumor associated macrophages

UR - http://www.scopus.com/inward/record.url?scp=84863961531&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863961531&partnerID=8YFLogxK

U2 - 10.3324/haematol.2011.055459

DO - 10.3324/haematol.2011.055459

M3 - Article

VL - 97

SP - 1080

EP - 1084

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 7

ER -